# Giant Cell Tumour of Clivus:

# A Rare Case Report

SWAPAN SHANTIRAM GOSWAMI<sup>1</sup>, SONAL JAIN<sup>2</sup>, SHALIN NAGORI<sup>3</sup>

(CC) BY-NC-ND

### **ABSTRACT**

Giant Cell Tumours (GCT) of the skull is rare, being less than 0.05% of all skeletal tumours. They are usually located in the middle cranial fossa affecting the temporal, sphenoid, petrosal and occipital bone. Clival GCT is rarer and 15 cases are described in the literature. Authors report a case of a female patient aged 20 years, who complained of headache with decrease in vision of left eye. Neurological examination revealed left optic nerve palsy. Laboratory test of Vitamin B12, blood urea, Serum Creatinine, Serum Electrolytes were within normal range. Complete blood count showed mild anaemia. The serum calcium and parathyroid hormones were within normal range. Complete blood count showed mild anaemia. The serum calcium and parathyroid hormones were within normal range. Computed Tomography (CT) scan and Magnetic Resonance Imaging (MRI) were done, which demonstrated expansile destructive lytic lesion involving sphenoid bone and clivus, reaching upto sellar, parasellar regions, sphenoid sinus and left posterior ethmoid sinus, effacing left optic foramina and posteriorly effacing prepontine cistern. The left internal carotid artery was partially encased by the mass. The tumour was partially removed by endoscopic trans-nasal trans-sphenoidal approach. Histopathology confirmed it as a benign GCT. Surgical treatment of clival GCTs are fraught with complication because of its close proximity to vital structures. High vascularity, potential malignant behaviour, inaccessibility and very few published cases preclude a definite outcome of this lesion. Histopathology is necessary to differentiate various lytic lesion like chordoma, aneurysmal bone cyst, invasive pituitary adenoma, chondrosarcoma and brown tumour (parathyroidism).

#### Keywords: Left optic nerve palsy, Osteoclastoma, Skull base tumour

## **CASE REPORT**

A 20-year-old female with one month history of headache and decreased vision in left eye. She had no history of trauma or surgery. No past medical history. Physical examination revealed overall good health. Neurological examinations revealed left optic nerve palsy. Laboratory tests were conducted, the blood biochemical tests included Urea-27 mg%, Serum Creatinine 0.8 mg%, Electrolytes Na+141 mµ/L, K+4.1 mµ/L, Cl+103 mµ/L. The complete blood count showed the following results Haemoglobin (Hb)-10.0 gm%, Total White Blood Cell (WBC) count-4200 cells/cumm, Differential count-61/30/04/05, Packed Cell Volume-31%, Mean Corpuscular Volume (MCV)-81.6 fL, Mean Corpuscular Haemoglobin (MCH)-26.3, Mean Corpuscular Haemoglobin Concentration (MCHC)-32.3%, Total Red Blood Cell (RBC) Count-3.8 Mil/µL, Red Cell Distribution Width (RDW)-13.3%, Platelet count-1.72 lac/cumm. Parathyroid hormone was 36.03 pg/mL (Normal range-15-65), Serum calcium was 9.2 mg/dL (Normal range 8.4-10.2). CT scan brain and Paranasal Sinuses (PNS) demonstrated expansile destructive lytic lesion which was seen involving sphenoid bone and clivus reaching up to sellar, parasellar regions, sphenoid sinus and left posterior ethmoidal sinus and effacing left optic foramina and posteriorly effacing prepontine cistern. Lesion was seen to partially encase the internal carotid artery. The mass lesion showed heterogenous enhancing soft tissue density component. Pituitary gland was not seen separately from the lesion. Small bulge was seen in the suprasellar region [Table/Fig-1].

Magnetic Resonance Imaging (MRI) scan was done using T1weighted (T1W), T2-weighted (T2W), Diffusion Weighted (DW), Gradient Recalled Echo (GRE) and Fluid Attenuated Inversion Recovery (FLAIR) sequences in various planes. Expansile destructive soft tissue intensity heterogeneously enhancing mass lesion was seen in body of sphenoid bone/clivus appearing hyperintense on both T2W and FLAIR sequences. Mass was extending into the prepontine cistern posteriorly and parasellar region and was pushing the pituitary gland cranially. The left internal carotid artery was partially encased by mass. Fullness was seen in the region of optic foramen on left side with minimal erosion.



The lesion was extending into sphenoid and left posterior ethmoid sinus. Chordoma and parathyroid tumour were considered in the differential diagnosis after clinical and radiological investigation.

Diagnostic cerebral angiography was done which showed clival tumour supplied by multiple small vessels of both left and right internal maxillary arteries and branches from left internal carotid artery through meningohypophyseal trunk. The tumour was removed using an endoscopic trans-nasal trans-sphenoidal method.

Then specimen was sent to the histopathology. Gross examination showed greyish white soft tissue bits aggregating  $2 \times 2 \times 0.1$  cm. Sections were stained with H&E.

Histopathological examination, showed bony spicules, fibro collagenous tissue and presence of tumour tissue with diffusely scattered multinucleated giant cells within a stroma of spindle cells [Table/Fig-2a-c]. GCT showed two populations of cells,

- 1. Mononuclear stromal cells
- 2. Osteoclast-type giant cells

suprasellar regions left optic foramina.

3. The giant cells were large and had over 20 or 30 nuclei



**[Table/Fig-2]:** a) The figure shows foci of bony spicules, fibro collagenous tissue and tumour tissue with evenly scattered multi-nucleated giant cells in a spindle to polygonal cell stroma (Stain: Haematoxylin and eosin, 40×). b) Giant Cell Tumour (GCT) with a mixture of mononuclear spindle cells and multi-nucleated giant cells. (Stain: Haematoxylin and eosin, 100×). c) High power appearance of Giant Cell Tumour (GCT). (Stain: Haematoxylin and eosin, 400×)

The stromal cells did not showed any nuclear atypia. The differential diagnosis after histopathological examination was aneurysmal bone cyst and GCT. Finally, the diagnosis of GCT of clivus was made. The treatment of the patient included surgical removal of tumour by endoscopic trans-nasal transsphenoidal method followed by radiotherapy in a dose of 54 Gy in 27 fraction over six weeks. The patient was well, till one year after operation in mid December 2020. Further contact was not possible.

### DISCUSSION

The GCT is tumours involving the bone and constitutes about 5% of all primary tumours of the skeletal system [1]. It usually occurs in the long bones around the joints in the epimetaphyseal regions of the bone on reaching maturity. Flat bone involvement of the skull, facial bones, pelvis and spine are rare, and GCT involving the skull constitutes <1% of the GCTs involving the skeletal system [2]. Clival GCT remains a very rare tumour forming 0.05% of primary skeletal tumour and less than 15 cases are described [3]. The tumour affects females and males equally. It is commonly seen between 20 years to 40 years of age.

GCTs are usually benign, but may be locally aggressive. Histopathologically, osteoclast like multi-nucleated giant cells are seen evenly dispersed in a background of stromal mononuclear cells and histiocytes. It is this stromal cell which forms the neoplastic component and may display malignant characteristics which may even metastasize rarely to the lungs [4]. GCTs are seen comparatively more in the Asian population affecting Chinese and Indians from 14.2 to 20.3% of the primary bone tumours [1,5]. Clinical features vary according to the site of tumour and involvement of particular cranial nerves I, II, III, IV, and VI. Past cases reported on GCT of clivus have been tabulated and discussed briefly in [Table/Fig-3] [2-4,6-16].

| Author,<br>publication<br>year, Reference | Age<br>(years/<br>sex) | Clinical features  | Size (cm)   | Duration<br>of<br>symptoms | MRI imaging T1/T2   | Vascularity   | Surgery                                      | RT  | Outcome                          | Follow-<br>up<br>(months) |
|---|------------------------|--|-------------|----------------------------|---|---|--|-----|----------------------------------|---------------------------|
| Wolfe JT et al.,<br>1983 [8]              | 16/Female              | Headache, diplopia,<br>visual disturbances   | NA          | 4-7 weeks                  | NA  | NA  | STR  | Yes | Alive with<br>residual<br>tumour | 96                        |
| Kattner KA et<br>al., 1998 [9]            | 9/Female               | Headache, diplopia   | NA          | 1 month                    | Space enhancing lesion<br>T2-hypointense and<br>isointense  | Moderately<br>vascular  | Biopsy (TSS)                                 | Yes | Alive with<br>residual<br>tumour | 12                        |
| Sharma RR et<br>al., 2002 [10]            | 18/Female              | Headache,<br>progressive hearing<br>loss, facial paresis   | NA          | 6 months                   | Space enhancing lesion<br>T1-isointense<br>T2-hyperintense  | Moderately<br>vascular  | NTR  | Yes | Alive                            | 12                        |
| Sharma RR et<br>al., 2002 [10]            | 12/Female              | Headache,<br>progressive hearing<br>loss, facial paresis,<br>nasal regurgitation,<br>nasal twang | NA          | 3 months                   | Space enhancing lesion<br>T1-isointense<br>T2-hyperintense  | Moderately<br>vascular  | GTR  | Yes | Alive                            | 12                        |
| Zorlu F et al.,<br>2006 [11]              | 14/Female              | Headache, diplopia   | 6*4*3.5     | 2.5<br>months              | Space enhancing lesion<br>Demostrated a lytic<br>expansile lesion                                 | NA  | STR  | Yes | Alive with<br>residual<br>tumour | 24                        |
| Gupta R et al.,<br>2008 [12]              | 17/Female              | Headache, diplopia,<br>amenorrhea, visual<br>disturbance   | 7.6*5.4     | 6 months                   | Space enhancing lesion  | Moderatey<br>vascular   | STR  | Yes | Alive with<br>residual<br>tumour | 24                        |
| SasagawaY et<br>al., 2012 [13]            | 26/Male                | Headache, diplopia   | 3*3         | NA                         | Space enhancing lesion<br>T1-isointense<br>T2-hyperintense  | Highly vascular,<br>massive<br>bleeding                         | STR  | Yes | Death                            | 9                         |
| lacoangeli M et<br>al., 2013 [14]         | 31/Male                | Headache, diplopia   | NA          | NA                         | Space enhancing lesion,<br>large GCT originating<br>from the clivus                               | Highly vascular,<br>massive<br>bleeding, ICA<br>rupture         | NTR  | No  | Alive with<br>residual<br>tumour | 24                        |
| Roy S et al.,<br>2013 [15]                | 19/Male                | Headache, facial<br>hyperasthesia  | 5.6*3.6*3.5 | 6 months                   | T1-large expansile<br>mass<br>T2-hyperintense   | High vascularity  | GTR  | Yes | Alive with<br>residual<br>tumour | 18                        |
| Agrawal A et<br>al., 2014 [6]             | 62/Male                | Headache, diplopia   | NA          | 3 months                   | Space enhancing lesion  | NA  | Endoscopy f/b<br>STR                         | NA  | No                               | NA                        |
| Shibao S et al.,<br>2015 [2]              | 25/Male                | Diplopia   | 5.1*3.1*4.9 | 1 month                    | Space enhancing lesion<br>T1-isointense<br>T2-hyperintense  | Highly vascular,<br>massive<br>bleeding, brain<br>stem invasion | STR  | Yes | Death                            | 31                        |
| Patibandla MR<br>et al., 2017 [4]         | 20/Male                | Left hemicranial<br>headache, vomiting,<br>dropping of eyelid                                    | NA          | 6 weeks                    | T1/T2- isointense   | NA  | STR  | Yes | Alive with<br>residual<br>tumour | 3                         |
| Satapathy A et<br>al., 2018 [16]          | 25/Male                | Headache, diplopia,<br>diminished vision   | 5.7*4.5*5.7 | 4 months                   | Space enhancing<br>lesion, large mass<br>centered on clivus                                       | Moderately<br>vascular  | GTR  | Yes | Alive                            | 8                         |
| Scotto di Carlo<br>F et al., 2018<br>[3]  | 55/Male                | Headache, vomiting   | NA          | NA                         | Space enhancing<br>lesion lobulated mass<br>originating from clivus<br>till sella and epitropheus | NA  | Sub-occipital<br>approach f/b<br>redosurgery | Yes | alive                            | 36                        |
| Scotto di Carlo<br>F et al., 2018<br>[3]  | 25/M                   | Headache, diplopia   | NA          | NA                         | Space enhancing lesion<br>lobulated mass  | NA  | Endoscopic<br>endonasal<br>approach          | No  | Alive                            | 72                        |

| Singh S et al.,<br>2020 [7]  | 35/Female | Headache, diplopia,<br>blurred vision | 4*2.5*0.5 | 6 months | Space enhancing<br>lesion homogenously<br>enhancing lesion                     | Highly vascular | Endoscopic<br>endonasal<br>trans-<br>sphenoidal<br>subtotal<br>resection | Yes<br>(60Gy/45fr) | Alive with<br>residual<br>tumour | 6  |
|--|-----------|---------------------------------------|-----------|----------|--|-----------------|--|--------------------|----------------------------------|----|
| Goswami SS<br>et al., 2021<br>(Present Case)   | 20/Female | Headache<br>diminished vision         | NA        | 1 month  | Space enhancing lesion<br>Expansile lytic lesion<br>T2/FLAIR -<br>hyperintense | NA              | Endoscopic<br>trans-nasal<br>transsphenoidal<br>resection                | Yes<br>(54Gy/27fr) | Alive with<br>residual<br>tumour | 12 |
| [Table/Fig-3]: Review of literature of GCT of clivus [2-4,6-16].<br>NA: Not available; STR: Subtotal resection; TSS: Trans-sphenoidal sinus surgery; GTR: Gross total resection; ICA: Internal carotid artery; NTR: Near total resection; GCT: Giant cell tumour; f/b: Followed by |           |                                       |           |          |  |                 |  |                    |                                  |    |

The patient presents with headache, visual disturbances, defects in visual fields, diplopia, weakness and paralysis of eye muscles, proptosis, loss of hearing, endocrine dysfunction and dysfunction of third and sixth cranial nerves [4,6].

In the present case, the patient had tumour involving the cranial nerves I and III and so presented with visual disturbances in the left eye. Histologically, the GCT showed scattered osteoclastic giant cells in the background of benign mononuclear stromal cells. Radical surgery with complete removal of the diseased bone is difficult in clival GCTs due to its peculiar anatomical location and approximation to adjacent vital neurovascular structures [1]. In the present case minimal invasive endoscopic surgery was carried out through the trans-nasal, transsphenoidal approach with partial resection of the tumour.

GCTs are resistant to radiotherapy and show a potential for malignant transformation. An adjunctive therapy may be recommended following partial tumour excision of skull base [1]. Chemotherapy with Adriamycin and bisphosphonates has been tried [4]. Radiographical and histological grading of the tumours don't correlate with the clinical behaviour. It is the extent of resection in surgery which affects the prognosis. Usually the recurrences occur within a couple of years following treatment hence follow-up is necessary. Availability of very few recorded; published cases preclude a definite prognosis of clival GCTs. With the present case, totally 16 cases have been identified [7]. The male to female ratio is equal. The patient's age ranged from 9 to 62 years. The duration of the tumour ranged from 1 to 6 months. The commonest complaints of the patients were headache with diplopia. The MRI findings revealed space enhancing lesions. The lesions were moderate to highly vascular. Fourteen patients had been treated with radiotherapy. Of the 16 patients, two have expired. The longest survivor is eight years on follow-up. In the present case the patient has been on follow-up for one year and is alive.

#### CONCLUSION(S)

GCT of clivus and sphenoid bone is very rarely seen. The tumour bone is located in the cranial cavity at inaccessible location and is in close approximation to vital structures, hampering complete excision. Histopathological examination is necessary due to presence of various osteolytic lesions in this location viz., chordoma, aneurysmal bone cyst, chondrosarcoma, parathyroid tumour and invasive pituitary adenoma. Malignant change in GCT has to be ruled out by histopathology as rare metastasis to lungs may occur.

#### REFERENCES

- [1] Zhao J, Qian T, Zhi Z, Li Q, Kang L, Wang J, et al. Giant cell tumour of the clivus: A case report and review of the literature. Oncol Lett. 2014;8(6):2782-86.
- [2] Shibao S, Toda M, Yoshida K. Giant cell tumours of the clivus: Case report and literature review. Surg Neurol Int. 2015;6(Suppl 25):S623-27.
- [3] Scotto di Carlo F, Divisato G, Iacoangeli M, Esposito T, Gianfrancesco F. The identification of H3F3A mutation in giant cell tumour of the clivus and the histological diagnostic algorithm of other clival lesions permit the differential diagnosis in this location. BMC Cancer. 2018;18(1):358.
- [4] Patibandla MR, Thotakura AK, Rao MN, Addagada GC, Nukavarapu MC, Panigrahi MK, et al. Clival giant cell tumour- A rare case report and review of literature with respect to current line of management. Asian J Neurosurg. 2017;12(1):78-81.
- [5] Saikia KC, Bhuyan SK, Borgohain M, Saikia SP, Bora A, Ahmed F. Giant cell tumour of bone: An analysis of 139 Indian patients. J Orthop Sci. 2011;16(5):581-88.
- [6] Agrawal A, Gali R, Shanthi V, Ramakrishna BA, Mohan KV. Giant cell tumour of the clivus with presence of epithelioid histiocytes. Asian J Neurosurg. 2014;9(1):48-49.
- [7] Singh S, Mankotia DS, Shankar KB, Siraj F. A rare tumour of clivus masquerading as pituitary adenoma. Asian J Neurosurg. 2020;15(4):1091-95.
- [8] Wolfe JT 3<sup>rd</sup>, Scheithauer BW, Dahlin DC. Giant-cell tumour of the sphenoid bone. Review of 10 cases. J Neurosurg. 1983;59(2):322-27.
- [9] Kattner KA, Stroink A, Gupta K, Fukushima T, Li C. Giant cell tumour of the sphenoid bone. Skull Base Surg. 1998;8(2):93-97.
- [10] Sharma RR, Mahapatra AK, Pawar SJ, Sousa J, Dev EJ. Craniospinal giant cell tumours: Clinicoradiological analysis in a series of 11 cases. J Clin Neurosci. 2002;9(1):41-50.
- [11] Zorlu F, Selek U, Soylemezoglu F, Oge K. Malignant giant cell tumour of the skull base originating from clivus and sphenoid bone. J Neurooncol. 2006;76(2):149-52.
- [12] Gupta R, Mohindra S, Mahore A, Mathuriya SN, Radotra BD. Giant cell tumour of the clivus. Br J Neurosurg. 2008;22(3):447-49.
- [13] Sasagawa Y, Tachibana O, Shiraga S, Takata H, Kinoshita E, Nojima T, et al. Secondary malignant giant cell tumour of the clivus: Case report. Clin Neurol Neurosurg. 2012;114(6):786-88.
- [14] Iacoangeli M, Di Rienzo A, Re M, Alvaro L, Nocchi N, Gladi M, et al. Endoscopic endonasal approach for the treatment of a large clival giant cell tumour complicated by an intraoperative internal carotid artery rupture. Cancer Manag Res. 2013;5:21-24. doi: 10.2147/cmar.s38768.
- [15] Roy S, Joshi NP, Sigamani E, Malik A, Sharma MC, Mohanti BK, et al. Clival giant cell tumour presenting with isolated trigeminal nerve involvement. Eur Arch Otorhinolaryngol. 2013;270(3):1167-71.
- [16] Satapathy A, Tripathi M, Chauhan RB, Gurnaani J, Mohindra S. Giant cell tumour at the clivus: Not an area 51. Neurol India. 2018;66(3):861-64.

#### PARTICULARS OF CONTRIBUTORS:

- 1. Professor, Department of Pathology, Smt. B.K. Shah Medical College, Sumandeep Vidyapeeth Deemed to be University, Vadodara, Gujarat, India.
- 2. Second Year Resident, Department of Pathology, Smt. B.K. Shah Medical College, Sumandeep Vidyapeeth Deemed to be University, Vadodara, Gujarat, India.
- 3. Second Year Resident, Department of Pathology, Smt. B.K. Shah Medical College, Sumandeep Vidyapeeth Deemed to be University, Vadodara, Gujarat, India.

# NAME, ADDRESS, E-MAIL ID OF THE CORRESPONDING AUTHOR: Dr. Shalin Nagori,

113, Gargi Sumandeep Vidyapeeth, Vadodara, Gujarat, India. E-mail: shalinnagori07@gmail.com

#### PLAGIARISM CHECKING METHODS: [Jain H et al.]

- Plagiarism X-checker: Oct 27, 2020
- Manual Googling: Jan 08, 2021
- iThenticate Software: Jan 23, 2021 (2%)

Date of Submission: Oct 23, 2020 Date of Peer Review: Nov 25, 2020 Date of Acceptance: Jan 09, 2021 Date of Online Ahead of Print: Jan 29, 2021 Date of Publishing: Feb 01, 2021

ETYMOLOGY: Author Origin

AUTHOR DECLARATION:

• Financial or Other Competing Interests: None